KR960014341A - 톡소플라즈마 곤디의 항원 - Google Patents

톡소플라즈마 곤디의 항원 Download PDF

Info

Publication number
KR960014341A
KR960014341A KR1019950034462A KR19950034462A KR960014341A KR 960014341 A KR960014341 A KR 960014341A KR 1019950034462 A KR1019950034462 A KR 1019950034462A KR 19950034462 A KR19950034462 A KR 19950034462A KR 960014341 A KR960014341 A KR 960014341A
Authority
KR
South Korea
Prior art keywords
gondii
peptide
acid sequence
nucleic acid
antibody
Prior art date
Application number
KR1019950034462A
Other languages
English (en)
Inventor
요체프 빌헬무스 데 하르트 요하네스
요세푸스 마리 쿨렌 마르쿠스
Original Assignee
에프.쥐.엠. 헤르만스ㆍ이.에이취. 레르링크
악조 노벨 엔.브이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에프.쥐.엠. 헤르만스ㆍ이.에이취. 레르링크, 악조 노벨 엔.브이. filed Critical 에프.쥐.엠. 헤르만스ㆍ이.에이취. 레르링크
Publication of KR960014341A publication Critical patent/KR960014341A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/45—Toxoplasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/20—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56905—Protozoa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/44—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from protozoa
    • G01N2333/45—Toxoplasma
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/822—Protozoa

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • Virology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

본 발명은 톡소플라즈마 곤디(Toxoplasma gondii)에 대한 항체와 면역반응하는 펩타이드, 이들 펩타이드를 암호화하는 핵산 서열, 이들 핵산 서열을 함유하는 재조합 벡터, 이 재조합 벡터, 이 재조합 벡터로 형질전환된 숙주 세포, 상기 펩타이드와 직접 반응하는 항체 또는 펩타이드를 함유하는 면역화학제제, T. gondii 감염 여부를 검출하기 위한 테스트 키트(test kit), 및 T. gondii 감염 예방용 백신에 관한 것이다.
본 발명은 특히 SEQ ID No. : 1에 나타낸 아미노산 서열의 일부를 함유하는 펩타이드를 제공한다.
본 발명의 바람직한 양태는 SEQ ID No. : 3 또는 5에 나타낸 아미노산 서열 일부분 이상을 함유하는 펩타이드이다.
본 발명의 펩타이드는 T. gondii 감염된 사람을 진단하는데 특히 적합하다.

Description

톡소플라즈마 곤디의 항원
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 니트로셀룰로즈 필터사엥 블롯팅된 단백질 SDS-PAGE 분석 결과이다.
제1A도는 알카라인 포스파타제 융합된 염소의 항-마우스 항체와 함께 배양된 필터 제1번을 나타내고,
제1B도는 알카라인 포스파타제 융합된 마우스의 항-사람 lgM과 함께 배양된 필터 제2번을 나타내고,
제1C도는 알카라인 포스파타제 융합된 마우스의 항-사람 IgG와 함께 배양된 필터 제3번을 나타낸다.
제2도는 클론 #114의 오리진(origin) 및 특이성을 분석한 결과이다.
제2A도는 티. 곤디(T. gondii)의 리보조말 RNA와 베로(Vero) 세포의 리보조말 RNA의 전기영동상의 이동성을 분석한 것이고,
제2B도는 모의(mock)로 감염된 베로세포에서 추출한 총 RNA 및 타키조이트(tachyzoites)의 RNA를 노던 블럿(Northern blot) 분석한 것이다.
제3도는 정제한 타키조이트(실시예 1) 및 감염되지 않은 베로세포에서 분리한 게놈 DNA 및 미토콘드리아 DNA 모두를 써던 블럿(Southern blot) 분석한 것이다.

Claims (17)

  1. SEQ IQ No. : 1에 나타난 아미노산 서열의 일부를 함유하는 특징으로 하는, 톡소플라즈마 곤디(Toxoplasma gondii)에 대한 항체와 면역반응하는 펩타이드.
  2. 제1항에 있어서, SEQ ID No. : 3 또는 5에 나타난 아미노산 서열 일부분 이상을 함유함을 특징으로 하는 펩타이드.
  3. SEQ ID No. : 2에 나타난 서열 일부를 함유함을 특징으로 하는 핵산 서열.
  4. 제3항에 있어서, SEQ ID No. : 4 또는 6에 나타난 서열 일부분 이상을 함유함을 특징으로 하는 핵산 서열.
  5. 제3항 또는 제4항의 핵산 서열을 함유하는 제조합 벡터.
  6. 제5항에 있어서, 핵산 서열이 발현 조절 서열과 작동가능하도록 연결됨을 특징으로 하는 재조합 벡터.
  7. 제3항 또는 제4항의 핵산 서열 또는 제5항 또는 제6항의 재조합 벡터로 형질 전환된 숙주 세포.
  8. 제7항의 숙주 세포를 배양하는 단계를 포함함을 특징으로 하는, 제1항 또는 제2항의 펩타이드의 발현 방법.
  9. 제1항 또는 제2항의 펩타이드와 면역반응하는 항체.
  10. 제9항에 있어서, 모노클로날 항체임을 특징으로 하는 항체.
  11. 제1항 또는 제2하으이 펩타이드를 함유함을 특징으로 하는 면역 화학제제.
  12. 제9항 또는 제10항의 항체를 함유함을 특징으로 하는 면역 화학제제.
  13. 제11항의 면역화학제제를 시액(test-fluid)과 접촉시키고, 시액중에 형성된 면역 복합체의 존부를 검출함을 특징으로 하는, 시액중의 T. gondii에 직접 반응하는, 시액중 T. gondii의 검출 방법.
  14. 제12항의 면역화학제제를 시액과 접촉시키고, 여기에. T. gondii에 직접 반응하는 항체를 접촉시킨후, 형성된 면역보합체의 존부를 검출함을 특징으로 하는, 시액중 T. gondii의 검출 방법.
  15. 제11항의 면역화학제제를 함유함을 특징으로 하는, T. gondii 검출용 테스트 키트(kit).
  16. 제12항의 면역화학제제를 함유함을 특징으로 하는 T. gondii 검출용 테스트 키트(kit).
  17. 제7항의 숙주 세포 또는 제1항 또는 제2하으이 펩타이드를 약학적 허용 담체와 함께 함유함을 특징으로 하는, T. gondii 예방용 백신.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019950034462A 1994-10-06 1995-10-05 톡소플라즈마 곤디의 항원 KR960014341A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP94202899.4 1994-06-10
EP94202899 1994-10-06

Publications (1)

Publication Number Publication Date
KR960014341A true KR960014341A (ko) 1996-05-22

Family

ID=8217262

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019950034462A KR960014341A (ko) 1994-10-06 1995-10-05 톡소플라즈마 곤디의 항원

Country Status (7)

Country Link
US (2) US5874526A (ko)
JP (1) JPH08301897A (ko)
KR (1) KR960014341A (ko)
AU (1) AU701173B2 (ko)
CA (1) CA2159958A1 (ko)
FI (1) FI954747A (ko)
ZA (1) ZA958366B (ko)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA958366B (en) * 1994-10-06 1996-04-24 Akzo Nobel Nv New toxoplasma gondii antigens
EP1485484A2 (en) * 2002-03-21 2004-12-15 Kenton S.r.l. Antigen fragments for the diagnosis of toxoplasma gondii
US7671555B2 (en) * 2005-12-21 2010-03-02 A. O. Smith Corporation Motor, a method of operating a motor, and a system including a motor
WO2012175410A1 (en) * 2011-06-24 2012-12-27 Centre National De La Recherche Scientifique Conditional knockout mutants of sortilin-like receptor in apicomplexan parasites and uses thereof

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2702491A (en) * 1953-05-01 1955-02-22 Paillard Sa Intermittent driving mechanism for the film of motion-picture cameras
EP0301961A1 (fr) * 1987-07-31 1989-02-01 Institut Pasteur Antigènes d'excrétion-sécrétion spécifiques de toxoplasma gondii, leurs produits d'expression, leurs procédés d'obtention et leurs applications diagnostiques et prophylactiques
WO1989005658A1 (fr) * 1987-12-24 1989-06-29 Transgene S.A. Proteines et leur procede de preparation, sequences d'adn, anticorps et leur application, poxvirus, cellules transformees ou infectees et compositions pharmaceutiques utiles dans la prevention de la toxoplasmose
US4877726A (en) * 1988-03-02 1989-10-31 Research Institute Of Palo Alto Medical Foundation Method for the detection of acute-phase toxoplasma infection
WO1992002624A1 (en) * 1990-08-10 1992-02-20 The Flinders University Of South Australia Cloning and expression of toxoplasma antigens and use of recombinant antigens
US5874526A (en) * 1994-06-10 1999-02-23 Akzo Nobel N.V. Toxoplasma gondii antigens
KR100215607B1 (ko) * 1989-12-08 1999-08-16 파이트 게, 부크 하 툭소플라스마곤디 항원,이의 제조 방법 및 이를 포함하는 진단제
KR100250944B1 (ko) * 1990-12-20 2000-04-15 장 스테판느 톡소플라스마 곤디(toxoplasma gondii)의 단백질 항원의 클로닝 및 발현

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4879213A (en) * 1986-12-05 1989-11-07 Scripps Clinic And Research Foundation Synthetic polypeptides and antibodies related to Epstein-Barr virus early antigen-diffuse
SG48953A1 (en) * 1988-03-09 1998-05-18 Univ Leland Stanford Junior Diagnostic genes for toxoplasmosis
US5665542A (en) * 1989-11-03 1997-09-09 Research Institute Of Palo Alto Medical Foundation Toxoplasma gondii P28 gene and methods for its use
FR2692282B1 (fr) * 1992-06-15 1995-07-13 Pasteur Institut Clonage du gene codant pour la proteine gp28.5 de t. gondii; fragments peptidiques issus de ladite proteine et leurs applications.
FR2702491B1 (fr) * 1993-03-12 1995-04-28 Pasteur Institut Clonage de gènes codant pour des antigènes d'excrétion-sécrétion P21 et P32 de toxoplasme, préparations de tels antigènes, fragments de ceux-ci et leurs applications.
FR2729960A1 (fr) * 1995-01-30 1996-08-02 Bio Merieux Polypeptides mimotopes de toxoplasma gondii et applications
JP2000506376A (ja) * 1996-01-26 2000-05-30 イノジェネティックス・ナムローゼ・フェンノートシャップ トキソプラズマ・ゴンジイ抗原Ｔｇ２０
US6329157B1 (en) * 1998-05-28 2001-12-11 Abbott Laboratories Antigen cocktails and uses thereof

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2702491A (en) * 1953-05-01 1955-02-22 Paillard Sa Intermittent driving mechanism for the film of motion-picture cameras
EP0301961A1 (fr) * 1987-07-31 1989-02-01 Institut Pasteur Antigènes d'excrétion-sécrétion spécifiques de toxoplasma gondii, leurs produits d'expression, leurs procédés d'obtention et leurs applications diagnostiques et prophylactiques
WO1989005658A1 (fr) * 1987-12-24 1989-06-29 Transgene S.A. Proteines et leur procede de preparation, sequences d'adn, anticorps et leur application, poxvirus, cellules transformees ou infectees et compositions pharmaceutiques utiles dans la prevention de la toxoplasmose
US4877726A (en) * 1988-03-02 1989-10-31 Research Institute Of Palo Alto Medical Foundation Method for the detection of acute-phase toxoplasma infection
KR100215607B1 (ko) * 1989-12-08 1999-08-16 파이트 게, 부크 하 툭소플라스마곤디 항원,이의 제조 방법 및 이를 포함하는 진단제
WO1992002624A1 (en) * 1990-08-10 1992-02-20 The Flinders University Of South Australia Cloning and expression of toxoplasma antigens and use of recombinant antigens
KR100250944B1 (ko) * 1990-12-20 2000-04-15 장 스테판느 톡소플라스마 곤디(toxoplasma gondii)의 단백질 항원의 클로닝 및 발현
US5874526A (en) * 1994-06-10 1999-02-23 Akzo Nobel N.V. Toxoplasma gondii antigens
US6420540B1 (en) * 1994-10-06 2002-07-16 Akzo Nobel N.V. Toxoplasma gondii antigens

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
논문(1995.6.28) *
논문(1996.4.4) *
논문(Exp Parasitol 1990 Jul;71(1):114-24) *
논문(J Histochem Cytochem 1992 Nov;40(11):1725-30) *
논문(Mol Biochem Parasitol 1990 Nov;43(1):97-106) *
논문(Mol Biochem Parasitol 1993 May;59(1):143-53) *
논문(Mol Biochem Parasitol 1994 Aug;66(2):283-96) *

Also Published As

Publication number Publication date
FI954747A (fi) 1996-04-07
JPH08301897A (ja) 1996-11-19
ZA958366B (en) 1996-04-24
US6420540B1 (en) 2002-07-16
AU3308495A (en) 1996-04-26
FI954747A0 (fi) 1995-10-05
CA2159958A1 (en) 1996-04-07
US5874526A (en) 1999-02-23
AU701173B2 (en) 1999-01-21

Similar Documents

Publication Publication Date Title
Santoro et al. Serodiagnosis of toxoplasma infection using a purified parasite protein (P30).
Kasper et al. Purification of a major membrane protein of Toxoplasma gondii by immunoabsorption with a monoclonal antibody.
Levin et al. Immunologic studies of the major nonimmunoglobulin protein of amyloid: I. Identification and partial characterization of a related serum component
Songa et al. A Card Agglutination Test (CATT) for veterinary use
Soto et al. Multicomponent chimeric antigen for serodiagnosis of canine visceral leishmaniasis
DE3485299D1 (de) Nachweis von antigen aktiven aminosaeurensequenzen.
US20090098528A1 (en) Method for determining early HCV seroconversion
BR9809443A (pt) Polipeptìdeo compreendendo uma porção antigênica de um antìgeno de m. tuberculosis, molécula de dna, vetor recombinante de expressão, célula hospedeira, processo para detecção de infecção de m. tuberculosis em uma amostra biológica, kit de diganóstico, anticorpo monoclonal, anticorpo policlonal, e, proteìna de fusão.
KR930019829A (ko) 엡스타인 바르 비루스(Epstein Barr Virus)와 관련된 펩티드 및 핵산 서열
Erlich et al. Identification of an antigen-specific immunoglobulin M antibody associated with acute Toxoplasma infection
JPH0767700A (ja) 合成ペプチドを使用するｈｔｌｖ試験
BR9712298A (pt) Polipeptìdeo, molécula de dna, vetor de expressão recombinante, célula hospedeira, processo para detectar infecção por m. tuberculosis em uma amostra biológica, kit diagnóstico, anticorpos monoclonal, e, policlonal, e, proteìna de fusão
Huang et al. High-level expression and purification of a truncated merozoite antigen-2 of Babesia equi in Escherichia coli and its potential for immunodiagnosis
KR950008537A (ko) 엡스타인 바 비루스(ebv)에 대한 항체의 검출용 진단제
KR960014341A (ko) 톡소플라즈마 곤디의 항원
Verhofstede et al. The infection-stage-related IgG response to Toxoplasma gondii studied by immunoblotting
Vervoort et al. Isotypic surface glycoproteins of trypanosomes.
Souza et al. Differences in reactivity of paracoccidioidomycosis sera with gp43 isoforms
US20030108563A1 (en) Reagents for the simultaneous detection of HCV core antigens and antibodies
Kamoun-Essghaier et al. Proteomic approach for characterization of immunodominant membrane-associated 30-to 36-kilodalton fraction antigens of Leishmania infantum promastigotes, reacting with sera from mediterranean visceral leishmaniasis patients
Günther et al. Antibodies to Lassa virus Z protein and nucleoprotein co-occur in human sera from Lassa fever endemic regions
Brenière et al. Immune response to Trypanosoma cruzi shed acute phase antigen in children from an endemic area for Chagas' disease in Bolivia
Pfeffer et al. Availability of hyperacetylated H4 histone in intact nucleosomes to specific antibodies.
KR940005666A (ko) C형 간염 바이러스를 분류하기 위한 항원성 펩티드 ,이 펩티드를 포함하는 키트 및 이 펩티드를 사용하여 c형 간염 바이러스를 분류하는 방법
Dion et al. A human protein related to the major envelope protein of murine mammary tumor virus: identification and characterization.

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application